Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic Leukemia Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir.

Autor:	Ford ES; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Simmons W; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA., Karmarkar EN; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA., Yoke LH; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Braimah AB; Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA., Orozco JJ; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA., Ghiuzeli CM; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Division of Hematology, Department of Medicine, University of Washington, Seattle, Washington, USA., Barnhill S; Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA., Sack CL; Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA., Benditt JO; Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA., Roychoudhury P; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA., Greninger AL; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA., Shapiro AE; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Global Health, University of Washington, Seattle, Washington, USA., Hammond JL; Pfizer, New York, NY, USA., Rusnak JM; Pfizer, New York, NY, USA., Dolsten M; Pfizer, New York, NY, USA., Boeckh M; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Liu C; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Cheng GS; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA., Corey L; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA.
Jazyk:	angličtina
Zdroj:	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2023 Mar 04; Vol. 76 (5), pp. 926-929.
DOI:	10.1093/cid/ciac868
Abstrakt:	A patient with B-cell acute lymphoblastic leukemia (ALL) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had persistent, progressive pneumonia with viremia after 5 months of infection despite monoclonal antibodies, intravenous (IV) remdesivir and prolonged oral steroids. Twenty days of nirmatrelvir/ritonavir and 10 days of IV remdesivir led to full recovery. Competing Interests: Potential conflicts of interest. J. H., J. M. R., and M. D. are employees of Pfizer. M. B. receives research support from GlaxoSmithKline and Gilead, and research support and consulting fees from Vir Biotechnology. A. L. G. reports contract testing to University of Washington (UW) from Abbott, Cepheid, Novavax, Pfizer, Janssen and Hologic and research support to UW from Gilead and Merck, outside of the described work. P. R. received speaking fees from Gates Foundation. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu